Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 30

1.

The long-term effect of tetrabenazine in the management of Huntington disease.

Fasano A, Cadeddu F, Guidubaldi A, Piano C, Soleti F, Zinzi P, Bentivoglio AR.

Clin Neuropharmacol. 2008 Nov-Dec;31(6):313-8. doi: 10.1097/WNF.0b013e318166da60.

PMID:
19050408
[PubMed - indexed for MEDLINE]
2.

Pathophysiology of Huntington's disease: from huntingtin functions to potential treatments.

Roze E, Saudou F, Caboche J.

Curr Opin Neurol. 2008 Aug;21(4):497-503. doi: 10.1097/WCO.0b013e328304b692. Review.

PMID:
18607213
[PubMed - indexed for MEDLINE]
3.

The current clinical management of Huntington's disease.

Phillips W, Shannon KM, Barker RA.

Mov Disord. 2008 Aug 15;23(11):1491-504. doi: 10.1002/mds.21971. Review.

PMID:
18581443
[PubMed - indexed for MEDLINE]
4.

A study of chorea after tetrabenazine withdrawal in patients with Huntington disease.

Frank S, Ondo W, Fahn S, Hunter C, Oakes D, Plumb S, Marshall F, Shoulson I, Eberly S, Walker F, Factor S, Hunt V, Shinaman A, Jankovic J.

Clin Neuropharmacol. 2008 May-Jun;31(3):127-33. doi: 10.1097/WNF.0b013e3180ca77ea.

PMID:
18520979
[PubMed - indexed for MEDLINE]
5.

Symptomatic treatment of Huntington disease.

Adam OR, Jankovic J.

Neurotherapeutics. 2008 Apr;5(2):181-97. doi: 10.1016/j.nurt.2008.01.008. Review.

PMID:
18394562
[PubMed - indexed for MEDLINE]
6.

Dopaminergic signaling and striatal neurodegeneration in Huntington's disease.

Tang TS, Chen X, Liu J, Bezprozvanny I.

J Neurosci. 2007 Jul 25;27(30):7899-910.

PMID:
17652581
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders.

Kenney C, Hunter C, Jankovic J.

Mov Disord. 2007 Jan 15;22(2):193-7.

PMID:
17133512
[PubMed - indexed for MEDLINE]
8.

Short-term effects of tetrabenazine on chorea associated with Huntington's disease.

Kenney C, Hunter C, Davidson A, Jankovic J.

Mov Disord. 2007 Jan;22(1):10-3.

PMID:
17078062
[PubMed - indexed for MEDLINE]
9.

Is history of depression a contraindication to treatment with tetrabenazine?

Kenney C, Hunter C, Mejia N, Jankovic J.

Clin Neuropharmacol. 2006 Sep-Oct;29(5):259-64.

PMID:
16960470
[PubMed - indexed for MEDLINE]
10.

Pharmacological management of Huntington's disease: an evidence-based review.

Bonelli RM, Wenning GK.

Curr Pharm Des. 2006;12(21):2701-20. Review.

PMID:
16842168
[PubMed - indexed for MEDLINE]
11.

Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial.

Huntington Study Group.

Neurology. 2006 Feb 14;66(3):366-72.

PMID:
16476934
[PubMed - indexed for MEDLINE]
12.

Critical periods of suicide risk in Huntington's disease.

Paulsen JS, Hoth KF, Nehl C, Stierman L.

Am J Psychiatry. 2005 Apr;162(4):725-31.

PMID:
15800145
[PubMed - indexed for MEDLINE]
13.

A rating scale for depression.

HAMILTON M.

J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62. No abstract available.

PMID:
14399272
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Tetrabenazine treatment for Huntington's disease-associated chorea.

Ondo WG, Tintner R, Thomas M, Jankovic J.

Clin Neuropharmacol. 2002 Nov-Dec;25(6):300-2.

PMID:
12469001
[PubMed - indexed for MEDLINE]
15.

Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine.

Verhagen Metman L, Morris MJ, Farmer C, Gillespie M, Mosby K, Wuu J, Chase TN.

Neurology. 2002 Sep 10;59(5):694-9.

PMID:
12221159
[PubMed - indexed for MEDLINE]
16.

A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease.

Huntington Study Group.

Neurology. 2001 Aug 14;57(3):397-404.

PMID:
11502903
[PubMed - indexed for MEDLINE]
17.

Reversal of tetrabenazine induced depression by selective noradrenaline (norepinephrine) reuptake inhibition.

Schreiber W, Krieg JC, Eichhorn T.

J Neurol Neurosurg Psychiatry. 1999 Oct;67(4):550. No abstract available.

PMID:
10610387
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Safety and tolerability of the free-radical scavenger OPC-14117 in Huntington's disease. The Huntington Study Group.

[No authors listed]

Neurology. 1998 May;50(5):1366-73.

PMID:
9595988
[PubMed - indexed for MEDLINE]
19.

Long-term effects of tetrabenazine in hyperkinetic movement disorders.

Jankovic J, Beach J.

Neurology. 1997 Feb;48(2):358-62.

PMID:
9040721
[PubMed - indexed for MEDLINE]
20.

Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group.

[No authors listed]

Mov Disord. 1996 Mar;11(2):136-42.

PMID:
8684382
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk